Cantata Bio
Enabling researchers & clinicians to solve tomorrow’s most challenging problems through novel, multiomic approaches.
Enabling researchers & clinicians to solve tomorrow’s most challenging problems through novel, multiomic approaches.
Cantata Bio is a startup focused on enabling researchers and clinicians to tackle future scientific challenges using innovative multiomic approaches. By leveraging proprietary technologies, platform solutions, services, and advanced bioinformatics and software, Cantata Bio aims to provide access to genomic and metagenomic information at unparalleled levels. The company's unique solutions cater to a wide array of complex problems, including chromatin topology analysis, structural variant detection, chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. With a customer base spanning epigenetics, developmental biology, cancer research, evolutionary biology, and infectious disease, Cantata Bio is making a positive impact in various scientific fields. Headquartered in Scotts Valley, California and Cambridge, Massachusetts, Cantata Bio was founded in 2022. For more details about Cantata Bio's technology and offerings, interested parties can visit www.cantatabio.com.
There is no investment information
No recent news or press coverage available for Cantata Bio.
We care about your data, and we'd love to use cookies make your experience better.
